J Zheng1, P F Shan, W Gu. 1. Department of Endocrinology and Metabolism, the Second Affiliated Hospital ZheJiang University College of Medicine, Hangzhou, 88 Jiefang Rd, Zhejiang 310009, P.R. China.
Abstract
OBJECTIVES: The role of metformin in the treatment of pregnant women with polycystic ovary syndrome (PCOS) is controversial. Therefore, we evaluated whether the use of metformin during pregnancy in women with PCOS could reduce pregnancy-related complications. RESEARCH DESIGN AND METHODS: MEDLINE was searched to retrieve relevant trials. In addition, reviews and reference lists of the retrieved articles were scanned for further appropriate studies. The primary outcome measure was the incidence of complications of pregnancy, which included early pregnancy loss (EPL), gestational diabetes (GDM), pre-eclampsia (PE), and pre-term delivery (PD). RESULTS: In total, eight studies with 1106 patients were included. The pooled odds ratio (OR) (95% confidence interval) of outcome for pregnant women with PCOS prescribed metformin were 0.32 (0.19-0.55) for EPL, 0.37 (0.25-0.56) for GDM, 0.53 (0.30-0.95) for PE and 0.30 (0.13-0.68) for PD. CONCLUSIONS: Metformin therapy throughout pregnancy decreased the OR of EPL, GDM, PE, and PD in pregnant PCOS women with no serious detrimental side effects.
OBJECTIVES: The role of metformin in the treatment of pregnant women with polycystic ovary syndrome (PCOS) is controversial. Therefore, we evaluated whether the use of metformin during pregnancy in women with PCOS could reduce pregnancy-related complications. RESEARCH DESIGN AND METHODS: MEDLINE was searched to retrieve relevant trials. In addition, reviews and reference lists of the retrieved articles were scanned for further appropriate studies. The primary outcome measure was the incidence of complications of pregnancy, which included early pregnancy loss (EPL), gestational diabetes (GDM), pre-eclampsia (PE), and pre-term delivery (PD). RESULTS: In total, eight studies with 1106 patients were included. The pooled odds ratio (OR) (95% confidence interval) of outcome for pregnant women with PCOS prescribed metformin were 0.32 (0.19-0.55) for EPL, 0.37 (0.25-0.56) for GDM, 0.53 (0.30-0.95) for PE and 0.30 (0.13-0.68) for PD. CONCLUSIONS:Metformin therapy throughout pregnancy decreased the OR of EPL, GDM, PE, and PD in pregnant PCOSwomen with no serious detrimental side effects.
Authors: S Khattab; I A Mohsen; I Aboul Foutouh; H S Ashmawi; M N Mohsen; M van Wely; F van der Veen; M Af Youssef Journal: Gynecol Endocrinol Date: 2011-01-19 Impact factor: 2.260
Authors: Bart C J M Fauser; Basil C Tarlatzis; Robert W Rebar; Richard S Legro; Adam H Balen; Roger Lobo; Enrico Carmina; Jeffrey Chang; Bulent O Yildiz; Joop S E Laven; Jacky Boivin; Felice Petraglia; C N Wijeyeratne; Robert J Norman; Andrea Dunaif; Stephen Franks; Robert A Wild; Daniel Dumesic; Kurt Barnhart Journal: Fertil Steril Date: 2011-12-06 Impact factor: 7.329
Authors: Denice S Feig; Kellie Murphy; Elizabeth Asztalos; George Tomlinson; Johanna Sanchez; Bernard Zinman; Arne Ohlsson; Edmond A Ryan; I George Fantus; Anthony B Armson; Lorraine L Lipscombe; Jon F R Barrett Journal: BMC Pregnancy Childbirth Date: 2016-07-19 Impact factor: 3.007
Authors: Aya Mousa; Tone Løvvik; Ijäs Hilkka; Sven M Carlsen; Laure Morin-Papunen; Kristiina Tertti; Tapani Rönnemaa; Argyro Syngelaki; Kypros Nicolaides; Hassan Shehata; Christy Burden; Jane E Norman; Janet Rowan; Jodie M Dodd; William Hague; Eszter Vanky; Helena J Teede Journal: BMJ Open Date: 2020-05-21 Impact factor: 2.692